APA (7th ed.) Citation

Patrikidou, A., Saieva, C., Lee-Ying, R., Nuzzo, P. V., Zarif, T. E., McClure, H., . . . Fornarini, G. (2024). Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer, 22(6), N.PAG. https://doi.org/10.1016/j.clgc.2024.102230

Chicago Style (17th ed.) Citation

Patrikidou, Anna, et al. "Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study." Clinical Genitourinary Cancer 22, no. 6 (2024): N.PAG. https://doi.org/10.1016/j.clgc.2024.102230.

MLA (9th ed.) Citation

Patrikidou, Anna, et al. "Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study." Clinical Genitourinary Cancer, vol. 22, no. 6, 2024, p. N.PAG, https://doi.org/10.1016/j.clgc.2024.102230.